Prophylaxis in factor IX deficiency product and patient variation
- 10 April 2003
- journal article
- clinical trial
- Published by Wiley in Haemophilia
- Vol. 9 (3), 279-284
- https://doi.org/10.1046/j.1365-2516.2003.00751.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pharmacokinetic analysis of plasma‐derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia BTransfusion, 2002
- Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxisHaemophilia, 2001
- Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's diseaseJournal of Internal Medicine, 1998
- Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxisHaemophilia, 1998
- Haemophilia prophylaxis in young patients–a long‐term follow‐upJournal of Internal Medicine, 1997
- Prophylactic Therapy for Hemophilia in a Developing Country, TurkeyPediatric Hematology and Oncology, 1997
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992
- Treatment of Hemophilia B with a New Clotting-Factor ConcentrateNew England Journal of Medicine, 1969